Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bausch + Lomb Inc.

http://www.bausch.com

Latest From Bausch + Lomb Inc.

BIOSECURE: What’s Coming Next?

The potential impact of the BIOSECURE Act continues to spread as the Biden administration increases its focus on China. But with BIO's top lobbyist and the top House sponsor of the legislation now headed out the door, the future of the bill remains uncertain.

China United States

OKYO Hits Multiple Dry Eye Endpoints, Plans Move Into Phase III

OKYO’s eye drop OK-101 has hit endpoints for ocular pain, tear film breakup time and conjunctival staining in Phase II, while demonstrating a placebo-like tolerability profile.

Clinical Trials Drug Approval Standards

Bausch + Lomb Dry Eye Franchise Ahead Of Growth Targets

Having acquired Xiidra from Novartis and getting US approval of Miebo in 2023, B+L’s two-product dry eye franchise delivered 66% year-over-year growth during Q4 2023.

Sales & Earnings Business Strategies

Sylentis Piles On Another Failure In Dry Eye

The PharmaMar subsidiary is the latest group to crash in a notoriously hard-to-treat disease, leaving Bausch + Lomb more firmly in command of the field.

Clinical Trials Ophthalmic
See All

Company Information

  • Other Names / Subsidiaries
    • Bausch & Lomb
    • Bausch + Lomb Technolas
    • ISTA Pharmaceuticals, Inc. (ISTA)
    • Laboratorio Pförtner Cornealent SACIF, Waicon
    • Technolas Perfect Vision GmbH
UsernamePublicRestriction

Register